scispace - formally typeset
S

Shinji Yoshitake

Researcher at ZymoGenetics

Publications -  6
Citations -  1254

Shinji Yoshitake is an academic researcher from ZymoGenetics. The author has contributed to research in topics: Complementary DNA & Nucleic acid sequence. The author has an hindex of 6, co-authored 6 publications receiving 1230 citations.

Papers
More filters
Journal ArticleDOI

Nucleotide sequence of the gene for human factor IX (antihemophilic factor B).

TL;DR: Two different human genomic DNA libraries were screened for the gene for blood coagulation factor IX by employing a cDNA for the human protein as a hybridization probe and found five overlapping lambda phages were identified that contained the genes for factor IX.
Journal ArticleDOI

The nucleotide sequence of the gene for human protein C.

TL;DR: A human genomic DNA library was screened for the gene for protein C by using a cDNA probe coding for the human protein using the dideoxy method and shown to span about 11 kilobases of DNA.
Journal ArticleDOI

Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA.

TL;DR: A lambda gt 11 library containing cDNA inserts prepared from human liver mRNA has been screened with an affinity-purified antibody to human histidine-rich glycoprotein (HRG) and then with a restriction fragment isolated from the 5' end of the largest cDNA insert obtained by antibody screening.
Journal ArticleDOI

Human liver fibronectin complementary DNAs: identification of two different messenger RNAs possibly encoding the alpha and beta subunits of plasma fibronectin.

TL;DR: Cellular fibronectin appears to have three extra peptide segments, encoded by the 75-base and 93-base segments in the IIIcs region and by the 270-base ED region, that are mostly absent in the liver fibronECTin.
Patent

Thrombin-activated tissue plasminogen activators

TL;DR: In this article, the proteins are cleavable by thrombin, the cleavage resulting in the stimulation of fibrinolytic activity are disclosed, and the modified proteins which may be modified in accordance with the present invention include tissue plasminogen activator, urokinase, and PLASminogen variants.